Literature DB >> 12543796

Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas.

Yoshifumi Okada1, Edward E Hurwitz, John M Esposito, Melissa A Brower, Catherine L Nutt, David N Louis.   

Abstract

Epidermal growth factor receptor (EGFR) gene amplification occurs in glioblastomas as so-called double minutes. Because double minutes are extrachromosomal fragments, selection pressures must operate to maintain high EGFR copy number over multiple cell divisions. In analyses of glioblastoma lysates, EGFR amplification has been observed almost exclusively in glioblastomas harboring wild-type TP53 genes, which raises the alternative hypotheses that TP53 mutation either prevents amplification or selects against maintenance of EGFR-amplified cells. To address these possibilities at the cellular level, we studied 14 glioblastomas for TP53 mutation and EGFR gene amplification status, using fluorescence in situ hybridization (FISH) for the latter. Remarkably, four of the six cases with TP53 mutation had isolated EGFR-amplified cells in different regions, demonstrating that EGFR amplification occurs frequently at the cellular level in TP53-mutant glioblastomas. Thus, TP53 mutation does not prevent EGFR amplification but does not facilitate selection of EGFR-amplified cells. Of the eight cases without TP53 mutation, five had widespread EGFR amplification. In four of these five cases, multiple regions of the tumor were available for examination; FISH demonstrated a gradation of EGFR amplification, with highly amplified cells, primarily at the invading edges rather than the relatively solid tumor centers, suggesting that EGFR overexpression, when selected for in vivo, may be related to tumor invasion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543796

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma.

Authors:  Mark Katakowski; Xuguang Zheng; Feng Jiang; Thomas Rogers; Alexandra Szalad; Michael Chopp
Journal:  Cancer Invest       Date:  2010-09-27       Impact factor: 2.176

2.  Multiparameter computational modeling of tumor invasion.

Authors:  Elaine L Bearer; John S Lowengrub; Hermann B Frieboes; Yao-Li Chuang; Fang Jin; Steven M Wise; Mauro Ferrari; David B Agus; Vittorio Cristini
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

3.  Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome.

Authors:  Piotr Rieske; Magdalena Zakrzewska; Wojciech Biernat; Jacek Bartkowiak; Arthur Zimmermann; Paweł Piotr Liberski
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  Intratumoral patterns of clonal evolution in gliomas.

Authors:  Ana Luísa Vital; Maria Dolores Tabernero; Inês Crespo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Maria Celeste Lopes; Alberto Orfao
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

5.  Cell density modulates SHC3 expression and survival of human glioblastoma cells through Fak activation.

Authors:  Alberto Azzalin; Elena Moretti; Eloisa Arbustini; Lorenzo Magrassi
Journal:  J Neurooncol       Date:  2014-07-26       Impact factor: 4.130

Review 6.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

7.  Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.

Authors:  Stefan Klingler; Baofeng Guo; Jun Yao; Haiyan Yan; Ling Zhang; Angelina V Vaseva; Sida Chen; Peter Canoll; James W Horner; Y Alan Wang; Ji-Hye Paik; Haoqiang Ying; Hongwu Zheng
Journal:  Cancer Res       Date:  2015-03-25       Impact factor: 12.701

8.  Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population.

Authors:  Saoussen Trabelsi; Imen Chabchoub; Iadh Ksira; Nadhir Karmeni; Nadia Mama; Samia Kanoun; Anna Burford; Alexa Jury; Alan Mackay; Sergey Popov; Noureddine Bouaouina; Slim Ben Ahmed; Moncef Mokni; Kalthoum Tlili; Hedi Krifa; Mohamed Tahar Yacoubi; Chris Jones; Ali Saad; Dorra H'mida Ben Brahim
Journal:  Mol Neurobiol       Date:  2016-03-09       Impact factor: 5.590

Review 9.  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

Authors:  Camilla Krakstad; Martha Chekenya
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

10.  Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.

Authors:  Dayane B Koshiyama; Patrícia Trevisan; Carla Graziadio; Rafael F M Rosa; Bibiana Cunegatto; Juliete Scholl; Valentina O Provenzi; Alexandre P de Sá; Fabiano P Soares; Maíra C Velho; Nelson de A P Filho; Ceres A Oliveira; Paulo R G Zen
Journal:  J Neurooncol       Date:  2017-08-30       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.